Second Intermezzo "Complete Response" Threatens Transcept's Partnership Payments
This article was originally published in The Pink Sheet Daily
Executive Summary
If approval is not gained by Sept. 23, partner Purdue Pharma will not have to make a $30 million milestone payment.
You may also be interested in...
Transcept Sees Road To Intermezzo Approval Without More Driving Studies
The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.
Transcept Sees Road To Intermezzo Approval Without More Driving Studies
The company says FDA "generally agreed" with a proposal for dosing reductions and labeling changes for the middle-of-the-night insomnia drug, which has received two "complete response" letters.
NuPathe Must Patch Together New Zelrix Launch Timetable After "Complete Response" Letter
FDA had questions related to chemistry, manufacturing and safety of migraine patch, company said.